Latest Product Updates and Feature Enhancements on Indegene iON
Indegene launches NEXT medical writing automation platform with GenAI
Indegene has launched NEXT Medical Writing Automation, a platform that uses generative AI to enhance medical writing. This tool integrates with existing systems to produce compliant documents efficie...ntly, allowing medical writers to focus on strategic tasks. It aims to streamline operations in clinical development and regulatory submissions by leveraging Indegene's AI engine, Cortex.
Strategic Partnerships and Integrations of Indegene iON
Indegene, Microsoft to deliver new life-sciences-focused business ...
Indegene and Microsoft have partnered to develop advanced commercial cloud applications for the life sciences sector. This collaboration integrates Microsoft Dynamics 365 for Sales with Indegene's Om...nipresence platform, creating a comprehensive CRM solution tailored for sales and medical representatives. The solution aims to enhance digital content management, analytics, and customer engagement, with availability expected by July 2017.
Indegene Selects Verified Market Research to Gain Strategic Insight into the Conjunctivitis Allergy Market
Indegene partnered with Verified Market Research to obtain strategic insights into the conjunctivitis allergy market. This collaboration aimed to support Indegene's advisory role for a client by prov...iding detailed market sizing, segmentation, and competitive analysis. The insights helped shape the client's portfolio expansion strategy, demonstrating Indegene's commitment to delivering precise and actionable data.
Indegene announces strategic partnership with Datavant
Indegene and Datavant have formed a strategic partnership to enhance patient recruitment for clinical trials, focusing on rare diseases. By integrating Datavant's data enrichment capabilities with In...degene's NEXT Patient Recruitment platform, the collaboration aims to streamline trial enrollment, reduce screen failures, and improve recruitment efficiency for biopharmaceutical companies.
Mergers, Acquisitions, and Business Moves by Indegene iON
Indegene Healthcare UK Limited Completes Asset Purchase Agreement Worth ...
Indegene Healthcare UK Limited, a subsidiary of Indegene Limited, completed a Trade and Asset Purchase Agreement with Trilogy Writing and Consulting Limited for GBP 1,90,679. This internal group cons...olidation involves acquiring trade and business assets between entities wholly owned by Indegene, aligning with SEBI regulations.
Indegene completes acquisition of Cake Health
Indegene has acquired Cake Health, a healthcare agency based in Austria, enhancing its global presence and capabilities in healthcare communications and digital marketing. This acquisition, Indegene'...s third in four years, strengthens its ability to support life sciences clients across Europe and the US, distinguishing it from creative-only agencies.
Indegene acquires Pennsylvania-based BioPharm
Indegene has acquired BioPharm, a specialized marketing services agency based in Pennsylvania, to enhance its commercialization portfolio with AdTech capabilities. This acquisition, executed through ...Indegene's subsidiary ILSL Inc., aims to integrate AI and digital advertising to offer precise, scalable solutions for pharma companies. BioPharm's expertise in omnichannel strategy and data-driven campaign execution strengthens Indegene's leadership in the data-driven omnichannel and media space.
Funding News and Financial Performance of Indegene iON
Indegene Q4 Net Profit Drops to ?797M Despite 32.8% Revenue Growth ...
Indegene reported a 32.8% increase in Q4 FY26 revenue to 10,034M, but net profit fell to 797M. The company achieved a full-year revenue of 35,105M, marking a 23.6% growth. The board proposed a final ...dividend of 2.25 per share, a 12.5% rise. An earnings call recording is available.
Indegene Q4 net profit falls 32% despite record ?1, 003 crore revenue, declares dividend
Indegene reported a 32.2% decline in Q4 net profit to 79.7 crore despite achieving record quarterly revenue of 1,003.4 crore, marking its first time surpassing 1,000 crore. The company declared a fin...al dividend of 2.25 per share. For FY26, revenue rose 23.6% to 3,510.5 crore, with adjusted EBITDA up 20.8% to 679.3 crore. Indegene secured significant deals, including one with an ACV over $3 million.
Indegene Q3 results: Revenue surges 31% to 942 crore but profit, margins dip
Indegene's Q3 FY26 results show a 30.8% revenue increase to 942 crore, marking its first $100 million-plus revenue quarter. Despite this, net profit fell 6.2% to 102.9 crore, and operating margins na...rrowed to 17%. Key achievements include three customers surpassing $25 million in annual revenue. Recent acquisitions of BioPharm and Warn & Co aim to enhance domain expertise.
Indegene Board to Approve Q3 2026 Financial Results
Indegene's Board of Directors will meet on January 29, 2026, to review and approve the unaudited financial results for Q3 2026. The meeting will also address share allotment under the RSU Scheme 2020.... The trading window for company securities is closed until 48 hours after the results are declared.
Leadership and Executive Team Updates at Indegene iON
Indegene appoints Jill DeSimone to Board of Directors
Indegene has appointed Jill DeSimone to its Board of Directors. DeSimone, with over 40 years of experience in the life sciences sector, previously held senior roles at Merck and Bristol Myers Squibb.... Her expertise is expected to support Indegene's growth in assisting life sciences clients with commercialization.
Corporate News and Organizational Updates on Indegene iON
Indegene expands its consulting practice to support life sciences organizations
Indegene has expanded its consulting practice to assist life sciences organizations in managing large-scale transformations. The company has appointed Gobin Chandra as the head of its Integrated Cons...ulting Practice. This expansion includes acquiring UK-based WARN & Co. to enhance its transformation consulting capabilities.